1. Home
  2. RBBN vs CABA Comparison

RBBN vs CABA Comparison

Compare RBBN & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ribbon Communications Inc.

RBBN

Ribbon Communications Inc.

HOLD

Current Price

$2.12

Market Cap

384.6M

Sector

Technology

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.94

Market Cap

319.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RBBN
CABA
Founded
1997
2017
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
384.6M
319.6M
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
RBBN
CABA
Price
$2.12
$2.94
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
7
Target Price
$4.67
$14.57
AVG Volume (30 Days)
676.8K
2.2M
Earning Date
04-28-2026
03-16-2026
Dividend Yield
N/A
N/A
EPS Growth
170.97
N/A
EPS
0.22
N/A
Revenue
N/A
N/A
Revenue This Year
$1.97
N/A
Revenue Next Year
$6.69
N/A
P/E Ratio
$9.98
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.83
$0.99
52 Week High
$4.31
$3.78

Technical Indicators

Market Signals
Indicator
RBBN
CABA
Relative Strength Index (RSI) 44.03 46.30
Support Level $2.07 $2.11
Resistance Level $2.88 $3.34
Average True Range (ATR) 0.10 0.21
MACD 0.01 -0.06
Stochastic Oscillator 19.44 17.50

Price Performance

Historical Comparison
RBBN
CABA

About RBBN Ribbon Communications Inc.

Ribbon Communications Inc provides communications technology to service providers and enterprises, offering software and high-performance hardware products, network solutions, and services for secure data and voice communications, as well as high-bandwidth networking for residential and enterprise customers across industries such as finance, education, government, utilities, and transportation. It operates through two segments: Cloud and Edge, which generate maximum revenue and deliver software-centric, cloud-native solutions for VoIP, VoLTE, VoNR, and unified communications, and IP Optical Networks, which support growing telecommunications traffic from 5G, distributed cloud computing, and other applications. The Company generates the majority of its revenue from the United States.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: